Enhanced Gemcitabine Delivery via Metformin-Derived Carbon Dots for Pancreatic Ductal Adenocarcinoma Therapy
Biomaterials Science · 2026
DOI: 10.1039/d6bm01301e ↗Kurz gefasst
Fachartikel in der Zeitschrift Biomaterials Science, 2026. Verfasst von Arya Ajith und 7 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 3.0).
Abstract (Originalsprache)
Pancreatic Ductal Adenocarcinoma (PDAC) is a highly aggressive cancer with a poor prognosis due to its dense stromal microenvironment, tumor heterogeneity, and rapid development of drug resistance. Gemcitabine (GEM), the...
Zitieren
APA
Ajith, A., Agatemor, C., Chen, J., Shiri, M., Yang, Z., Dixon, L., Wang, K., & Leblanc, R. M. (2026). Enhanced Gemcitabine Delivery via Metformin-Derived Carbon Dots for Pancreatic Ductal Adenocarcinoma Therapy. Biomaterials Science. https://doi.org/10.1039/d6bm01301e
Vancouver
Ajith A, Agatemor C, Chen J, Shiri M, Yang Z, Dixon L, et al. Enhanced Gemcitabine Delivery via Metformin-Derived Carbon Dots for Pancreatic Ductal Adenocarcinoma Therapy. Biomaterials Science. 2026. doi:10.1039/d6bm01301e
BibTeX
@article{Ajith2026,
author = {Ajith, Arya and Agatemor, Christian and Chen, Jiuyan and Shiri, Mehrdad and Yang, Zixin and Dixon, Lydia and Wang, Kun and Leblanc, Roger M.},
title = {Enhanced Gemcitabine Delivery via Metformin-Derived Carbon Dots for Pancreatic Ductal Adenocarcinoma Therapy},
journal = {Biomaterials Science},
year = {2026},
doi = {10.1039/d6bm01301e}
}
EUVIMED